RT Journal Article
SR Electronic
T1 Unresectable Perihilar Cholangiocarcinoma: Multimodal Palliative Treatment
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2747
OP 2753
VO 33
IS 6
A1 CRISTINA MOSCONI
A1 MATTEO RENZULLI
A1 EMANUELA GIAMPALMA
A1 ANDREA GALUPPI
A1 CATERINA BALACCHI
A1 GIOVANNI BRANDI
A1 GIORGIO ERCOLANI
A1 GIAMPAOLO BIANCHI
A1 RITA GOLFIERI
YR 2013
UL http://ar.iiarjournals.org/content/33/6/2747.abstract
AB Aim: To evaluate the survival of patients with unresectable perihilar cholangiocarcinoma (PHC) treated with multimodal palliative approaches. Patients and Methods: thirty-two patients were enrolled in a multimodal protocol including: bilateral biliary drainage; Yridium-192 intraluminal brachytherapy (BT); metal biliary stenting; external-beam radiotherapy (EBRT); systemic chemotherapy (ChT). All patients underwent BT and biliary stenting: this was the only treatment for 14 patients, it was combined with EBRT in 11, and with EBRT and ChT in seven. Mean and median survival, complication rates and duration of hospital stay were calculated for each group. Results: BT with EBRT and ChT obtained the best median (15 months) and one year (71.42%) survival followed by BT with EBRT (14 months and 63.63%, respectively). BT with EBRT in a total dose of 54-60 Gy, with or without ChT, led to a significantly higher median survival rate (14 months) than that for BT alone (seven months). Conclusion: BT with EBRT, with or without ChT, improves survival and should be considered as a suitable alternative to palliative surgery for patients with unresectable perihilar cholangiocarcinoma.